Coherus Oncology, Inc.
CHRS
$1.20
$0.065.26%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 14.31M | 12.31M | 12.75M | 11.57M | 10.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.31M | 12.31M | 12.75M | 11.57M | 10.25M |
| Cost of Revenue | 4.24M | 3.81M | 4.05M | 3.72M | 3.40M |
| Gross Profit | 10.07M | 8.50M | 8.70M | 7.85M | 6.86M |
| SG&A Expenses | 20.95M | 23.10M | 21.01M | 22.83M | 26.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.64M | 48.46M | 56.03M | 53.80M | 55.74M |
| Operating Income | -32.33M | -36.15M | -43.28M | -42.23M | -45.49M |
| Income Before Tax | -33.35M | -36.94M | -46.35M | -44.52M | -44.86M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.35M | -36.94M | -46.35M | -44.52M | -44.86M |
| Earnings from Discontinued Operations | 12.72M | -1.39M | 8.70M | 8.99M | 342.63M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.63M | -38.33M | -37.64M | -35.53M | 297.77M |
| EBIT | -32.33M | -36.15M | -43.28M | -42.23M | -45.49M |
| EBITDA | -31.47M | -35.27M | -42.38M | -41.27M | -44.47M |
| EPS Basic | -0.13 | -0.28 | -0.31 | -0.31 | 2.57 |
| Normalized Basic EPS | -0.13 | -0.17 | -0.23 | -0.23 | -0.24 |
| EPS Diluted | -0.13 | -0.28 | -0.31 | -0.31 | 2.57 |
| Normalized Diluted EPS | -0.13 | -0.17 | -0.23 | -0.23 | -0.24 |
| Average Basic Shares Outstanding | 154.82M | 136.40M | 120.37M | 116.23M | 116.08M |
| Average Diluted Shares Outstanding | 154.82M | 136.40M | 120.37M | 116.23M | 116.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |